Stereotaxis (STXS) Projected to Post Earnings on Monday

Stereotaxis (NYSEAMERICAN:STXS) is projected to post its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect Stereotaxis to post earnings of ($0.06) per share and revenue of $9.24 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Stereotaxis Stock Performance

Shares of STXS opened at $2.16 on Monday. The firm has a fifty day moving average of $2.34 and a 200-day moving average of $2.61. The company has a market cap of $201.57 million, a price-to-earnings ratio of -7.71 and a beta of 1.38. Stereotaxis has a 1 year low of $1.54 and a 1 year high of $3.59.

Institutional Investors Weigh In On Stereotaxis

A number of institutional investors and hedge funds have recently modified their holdings of STXS. Vanguard Group Inc. boosted its position in shares of Stereotaxis by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after purchasing an additional 138,482 shares during the period. Arbiter Partners Capital Management LLC boosted its holdings in shares of Stereotaxis by 1.1% in the fourth quarter. Arbiter Partners Capital Management LLC now owns 2,883,856 shares of the company’s stock worth $6,633,000 after buying an additional 30,000 shares during the period. Geode Capital Management LLC increased its position in shares of Stereotaxis by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,565,182 shares of the company’s stock worth $3,601,000 after acquiring an additional 55,491 shares in the last quarter. State Street Corp increased its position in shares of Stereotaxis by 11.4% in the fourth quarter. State Street Corp now owns 891,886 shares of the company’s stock worth $2,051,000 after acquiring an additional 91,453 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Stereotaxis during the fourth quarter valued at approximately $1,380,000. 45.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on STXS shares. Roth Mkm reaffirmed a “buy” rating and issued a $4.00 price target on shares of Stereotaxis in a research note on Wednesday, November 12th. Citizens Jmp started coverage on Stereotaxis in a research report on Tuesday, December 16th. They set a “market outperform” rating and a $4.00 price target on the stock. Citigroup initiated coverage on Stereotaxis in a report on Tuesday, December 16th. They issued an “outperform” rating for the company. Finally, UBS Group set a $4.00 target price on Stereotaxis in a report on Wednesday, November 5th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $4.00.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.